| Autor: |
Vrtala, Susanne, Hirtenlehner, Kora, Susani, Markus, Akdis, Mübeccel, Kussebi, Fatimah, Akdis, Cezmi A., Blaser, Kurt, Hufnagl, Peter, Binder, Bernd R., Politou, Anastasia, Pastore, Annalisa, Vangelista, Luca, Sperr, Wolfgang R., Semper, Hans, Valent, Peter, Ebner, Christof, Kraft, Dietrich, Valenta, Rudolf |
| Zdroj: |
The FASEB Journal; September 2001, Vol. 15 Issue: 11 p2045-2047, 3p |
| Abstrakt: |
An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life‐threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1‐specific B cell and T‐cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients’ IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text